Transfusion-associated graft-versus-host disease

Size: px
Start display at page:

Download "Transfusion-associated graft-versus-host disease"

Transcription

1 CHAPTER 6 Transfusion-associated graft-versus-host disease Eric A. Gehrie, 1 Edward L. Snyder, 1 & Alex B. Ryder 2 1 Department of Laboratory Medicine, Yale School of Medicine, Yale University; and Blood Bank, Yale-New Haven Hospital, New Haven, CT, USA 2 Department of Pediatrics and Department of Pathology, University of Tennessee Health Science Center, La Bonheur Children s Hospital, TN, USA Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare but almost uniformly lethal complication of blood transfusion. Although the graft-versus-host disease (GVHD) that occurs after allogeneic bone marrow transplantation and TA-GVHD share some clinical similarities, GVHD after bone marrow transplant is not uncommon and often responds positively to immunosuppression. 1 The much rarer TA-GVHD, however, in contradistinction to bone marrow GVHD, is associated with destruction of the recipient s bone marrow, does not respond to immunosuppressive therapy, 1 and is generally fatal. 2 Because there are no effective treatments for TA- GVHD, management of this complication focuses almost entirely on prevention by irradiation of cellular blood components (whole blood, red blood cells [RBCs], granulocytes, and platelets) that are intended for susceptible recipients. Over the past 1 15 years, the use of irradiation in high-risk situations has reduced the incidence of TA-GVHD in the Western world and Japan to almost undetectable levels. In this chapter, we review the pathophysiology and incidence of TA-GVHD, characteristics of blood transfusion recipients that make them susceptible to the development of TA-GVHD, and strategies to prevent, diagnose, and treat TA-GVHD. Pathophysiology of TA-GVHD The development of TA-GVHD requires infusion of viable allogeneic donor ( nonself ) lymphocytes, which subsequently engraft, proliferate, and attack recipient ( self ) tissues. Unlike GVHD, in which the transplanted donor hematopoietic cells in the engrafted marrow are the cells that mediate the attack on host (recipient) tissues, TA-GVHD results in destruction of both the host tissues and host bone marrow by donor T lymphocytes that engraft in the recipient following transfusion. It is the host bone marrow aplasia that occurs only in TA-GVHD that drives its lethality. The biologic basis for the differentiation of self and nonself is based on immune recognition of specific cell surface proteins, most importantly human leukocyte antigens (HLA), which are expressed on the surface of both immune and non-immune cell types. In most situations, transfused donor lymphocytes are identified by the host immune system due to their expression of non-self HLA proteins. The recognition of non-self HLA proteins by the host immune system usually leads to attack and death of donor lymphocytes contained in the transfused unit of blood or platelets. However, in rare situations, transfused donor lymphocytes are not recognized as non-self by the recipient immune system. If the transfused donor lymphocytes are sufficiently viable to engraft and proliferate within the recipient, TA-GVHD can result. Partially because TA-GVHD is exceptionally rare, the precise circumstances needed to induce TA-GVHD are not known. Transfusion-associated microchimerism (TA-MC) is a condition that occurs after transfusion of cellular blood components, in which a small number of donor allogeneic lymphocytes proliferate within a host and remain detectable for years. TA-MC is associated with perhaps 1% of patients transfused after sustaining traumatic injury, but is not known to have any clinical sequelae. 3 Distinguishing the factors that influence why T-lymphocyte engraftment sometimes results in severe disease (TA-GVHD), and sometimes results in no disease manifestations (TA-MC), is the subject of ongoing investigation. In many cases, the presence of severe acquired or congenital immune deficiency in the transfusion recipient serves as a prerequisite to the development of TA-GVHD. TA-GVHD, however, has also been reported to occur in the absence of a recognized immune deficiency, particularly in situations where the blood donor is homozygous for HLA antigens for which the recipient is heterozygous. 2 In this scenario, all HLA antigens expressed by the donor are also expressed by the host, but the host expresses HLA antigens that are not expressed by the donor. This can result in unidirectional tolerance, where donor lymphocytes are spared from attack by the host immune system, whereas host tissues are left vulnerable to attack by donor lymphocytes and their progeny (Figure 6.1). Incidence of TA-GVHD At present, TA-GHVD is an extremely rare phenomenon. In the United Kingdom, more than 4 million cellular blood components have been transfused since 1999 (Table 6.1). During that interval, there has been only one case of reported TA-GVHD. Similar data compiled by the US Food and Drug Administration (FDA) identified only three cases of fatal TA-GVHD in the United States from 25 to 213, during which time almost 15 million cellular blood components were transfused (Table 6.2). In both the United Kingdom and the United States, widespread use of blood component irradiation in at-risk populations has contributed to the low incidence of TA-GVHD. In Japan, there is substantially less HLA diversity than in the United States or the United Kingdom. In addition, Japan has a high rate of directed-donor blood collections where relatives donate Rossi s Principles of Transfusion Medicine, Fifth Edition. Edited by Toby L. Simon, Jeffrey McCullough, Edward L. Snyder, Bjarte G. Solheim, and Ronald G. Strauss. 2 John Wiley & Sons, Ltd. Published 2 by John Wiley & Sons, Ltd. 68

2 Chapter 6: Transfusion-associated graft-versus-host disease 681 Recipient Cell 9 HLA B37 Donor Cell Immune Attack on Recipient Cell Mediated by Detection by Donor Cell of non-self HLA type Figure 6.1 Unidirectional tolerance occurs when donor lymphocytes mediate an attack on host tissues while simultaneously being viewed as self by the host immune system. In this example, recipient cells expressing 9 and HLA B37 antigens are attacked by donor lymphocytes that do not express these antigens; however, donor-derived and expressing cells are not targeted by the recipient immune system because these antigens are also expressed by recipient cells. Scenario depicted similar to a case report by Benson et al. 49 Table 6.1 UK reports of cellular blood component infusions and TA-GVHD to the serious hazards of transfusion hemovigilance network, Year RBCs Transfused (UK) Platelets Transfused (UK) Reports of TA-GVHD (UK) 213 2,43,46 312, ,146, ,737 1 (Fatal) 211 2,2,137 31, ,18, , ,29, , ,4, , ,235, , ,3, , ,428, , ,67,41 264, ,678,98 251, ,679, , ,76,37 25,259 1 (Fatal) ,737, , ,386, ,25 4 (All fatal) ,75, 33, 4 (All fatal) ,43, 252, 4 (All fatal) Total 4,872,667 4,579, Universal leukodepletion introduced in Reference blood for other family members. 4,5 As a result, Japan has historically had a higher rate of TA-GVHD, and a large proportion of TA-GVHD case reports are published by Japanese authors. 4,5 Indeed, in Japan prior to the routine irradiation of blood components, TA-GVHD had a calculated expected incidence of 1 in 874 transfusions when donor and recipient were unrelated, and 1 in 12 Table 6.2 Reports of TA-GVHD to US FDA compared to annual estimates of transfusion of cellular blood components, Year Number of RBCs Transfused (US) Platelets Transfused (US) Reports of Fatal TA-GVHD to FDA 213 NR NR 212 NR NR ,785, 2,9, 1 21 NR NR 1 29 NR NR 28 15,14, 2,21, 27 NR NR 26 14,65, 1,731, 25 NR NR 1 Total 13,347, (est) Apheresis equivalent units. NR, Not reported; est, estimate.,763, (est) , 46, 47, 48 Reference when donor and recipient were a mother child pair. 4 Routine irradiation of cellular blood components was introduced in Japan in 1998, and there have been no published reports of TA-GVHD in Japan between 1999 and Similar scenarios are found in other countries where there is substantially less HLA diversity among the donor recipient population. Clinical scenarios associated with TA-GVHD Patients without recognized immunodeficiency syndromes Prior to the widespread irradiation of cellular blood components in Japan, the rate of TA-GVHD in Japan was higher than in Western Europe or the United States. The Japanese medical literature describes numerous cases of TA-GVHD in patients without a recognized immunodeficiency. 6 Uchida et al. reported that, among 66 confirmed cases of TA-GVHD in Japan from 1992 to 1999, 65 of the patients were not considered by the study authors to be immunosuppressed. 2 The majority of these patients received transfusions either during the treatment of solid tumors or for surgical or traumatic bleeding episodes. 2 Similarly, Juji et al. reported 96 cases of TA-GVHD among immunocompetent Japanese undergoing cardiac surgery between 1981 and There are several factors that appear to play a role in the pathogenesis of TA-GVHD among patients without recognized immunodeficiency syndromes. One contributing factor is likely the relative HLA homogeneity in Japan, where many of the cases were reported. A study of 655 Japanese found the frequency of the most common HLA haplotype to be 7.5%, and the second most common HLA haplotype had a frequency of 5%. In contrast, the same study found the frequency of the most frequent HLA haplotype among US Caucasians to be only 4%, and the most common HLA haplotype among Italians was identified in only 2.2% of the population. 4 It is likely that the lack of HLA diversity among the Japanese population resulted in unidirectional tolerance more frequently in Japan than in other parts of the world, helping to explain the historically high levels of TA-GVHD in Japan prior to widespread irradiation of cellular blood components. However, the calculated incidence of TA-GVHD based on HLA similarity is much lower than the actual incidence of TA-GVHD, 1,8 indicating that a lack of HLA diversity is likely only one of many factors that influence the pathogenesis of TA-GVHD. Another factor that may contribute to TA-GVHD in some patients is trauma or major surgery, particularly cardiac surgery. 9 Although the mechanism of immune suppression, if any, contributing to TA-GVHD in these patient populations is not known, it has been reported that hospitalized patients, compared to healthy volunteers, are less likely to generate antibodies after exposure to

3 682 Section V: Part II: Other hazards allogeneic, minor blood group antigens via transfusion. 1 Consequently, it is possible that although hospitalization and surgery help to prevent alloimmunization, they simultaneously increase the risk of developing TA-GVHD. This hypothesis may also help explain the reported relatively high (1%) incidence of TA-MC seen after transfusion following a traumatic injury. 3 Besides cardiac surgery and HLA similarity between donor and recipient, other factors that have been associated with TA-GVHD in immunocompetent individuals have also been described, including transfusion of recently collected (<72 hours old) blood, 6 use of blood collected from first- or second-degree relatives, 6 and use of nonirradiated cellular blood products. 11 These factors likely enhance the probability of developing TA-GVHD by either enhancing the viability or dose of transfused lymphocytes (e.g., using fresh or non-leukoreduced or non-irradiated blood components) or increasing the likelihood of HLA similarity between donor and recipient (e.g., using blood from close family relations). A murine model of TA-GVHD has been described. 1 TA-GVHD in immunosuppressed patients Although cases of TA-GVHD are reported among patients without recognized immunodeficiency, many more reported cases involve patients who are profoundly immunosuppressed. 8 Among immunosuppressed patients, those considered at highest risk for the development of TA-GVHD include patients with severe T-cell immunodeficiency syndromes (e.g., severe combined immunodeficiency or DiGeorge syndrome), patients undergoing allogeneic or autologous bone marrow transplant, patients diagnosed with Hodgkin s lymphoma or aplastic anemia on immunosuppressive therapy, neonates, a fetus receiving intrauterine transfusions, and patients being treated with purine analogs (fludarabine, cladribine, or deoxycoformicin) or alemtuzumab (anti-cd52). 8,12,13 Although rare cases of TA-GVHD have been reported in patients after organ transplantation, undergoing treatment for solid tumors, or with either non-hodgkin s lymphoma or acute leukemia (without stem cell transplantation), the risk is generally considered to be lower compared to the first groups listed above. 12,13 No cases of TA- GVHD attributed only to immunodeficiency caused by HIV/AIDS (in the absence of other conditions listed above) have been reported in the medical literature to date. 12,13 National guidelines from the United Kingdom and Australia address the importance of ensuring that all cellular blood products used in high-risk settings are appropriately irradiated. 12,13 In a recent case report in 211 in the United Kingdom, two intrauterine transfusions were administered to a fetus (hemoglobin4.4g/dl)at21weeksgestationwhowasanemicduetoa maternal parvovirus infection. The transfusions were performed using a total of 33 ml of non-leukoreduced, nonirradiated blood that had been collected from the mother. 14,15 Although cellular blood components (including whole blood) intended for intrauterine transfusions are generally leukoreduced and irradiated in the United Kingdom, these product modifications were not made in this case due to the emergent need for the transfusions. At 32 weeks gestation, the fetus was delivered hydropic and pancytopenic. Two months after birth, a bone marrow biopsy revealed an aplastic marrow, and maternal engraftment was detected by chimerism studies. HLA typing performed on the mother found her to be HLA homozygous and showed unidirectional tolerance for her child. The neonate was diagnosed with TA-GVHD and died despite attempted allogeneic stem cell transplantation using stem cells collected from the mother. Diagnosis of TA-GVHD The most common signs and symptoms of TA-GVHD are fever, erythema, pancytopenia, bone marrow aplasia, diarrhea, and hepatitis; these generally occur within 1 2 weeks of transfusion but can be seen up to 3 days after transfusion. 2,5 The case fatality rate for TA-GVHD approaches 1%. 2,14, 21 The diagnosis of TA-GVHD requires a high degree of clinical suspicion, particularly given the relatively long latency period between transfusion and the development of symptoms (up to 3 days). In addition, if patients are critically ill at the time of their transfusion, it may be difficult to differentiate the clinical signs of TA-GVHD from their underlying illness. For these reasons, TA-GVHD may be underdiagnosed. 22 Nonetheless, a diagnosis of TA-GVHD should be considered in any patient with fever, erythema, neutropenia, diarrhea, and hepatitis within 3 days of a transfusion with nonirradiated cellular blood products (whole blood, RBCs, granulocytes, or platelets). It is notable that reports of TA-GVHD have never been attributed to transfusions with plasma, cryoprecipitate, factor concentrates, albumin, intravenous immunoglobulin, or previously frozen, deglycerolized RBCs. This is presumably due to the absence of sufficient viable donor lymphocytes in these products. 12 If TA-GVHD is suspected clinically, donor lymphocytes can be differentiated from host lymphocytes by measuring differences in restriction fragment length polymorphisms or numbers of short tandem repeats between the donor and the host. These tests can be performed using molecular assays that are routinely utilized to detect donor recipient chimerism in patients who have undergone allogeneic stem cell transplantation. 22 One strategy is to biopsy both affected and unaffected patient tissues and to compare the results to samples obtained from the blood donor (if available). 12 In older reports, detection of the Y chromosome was used to diagnose TA-GVHD resulting from a blood transfusion from a male donor to a female recipient. 23 Today, this approach is considered to be relatively insensitive in most circumstances, and would be of no use in cases of TA-GVHD suspected in male recipients, in patients who have undergone a sex-mismatched stem cell transplant, or in cases involving transfusion of a blood component collected from a female donor. Prevention of TA-GVHD Although the introduction of universal leukoreduction is associated temporally with a reduction in the reported incidence of TA- GVHD, cases of TA-GVHD have been reported in patients receiving leukoreduced (but nonirradiated) cellular blood transfusions. 24 In addition, the minimum dose of lymphocytes required to cause TA-GVHD in humans is not precisely known, and it may be influenced by factors that are not likely to be fully known prior to transfusion. These factors include the degree of HLA match between donor and recipient, the viability of the remaining transfused lymphocytes, and the degree of immunosuppression of the recipient. Consequently, leukoreduction alone is not considered to be sufficient prophylaxis against TA-GVHD; irradiation of cellular blood components is the only widely recognized method to prevent TA-GVHD in all cellular blood components. 12

4 Chapter 6: Transfusion-associated graft-versus-host disease 683 In the United States, in order to render lymphocytes contained in RBCs, platelets, granulocytes, or whole blood incapable of engraftment, it is an AABB Standard that for blood component irradiation, 25 Gy must be directed at the center of the blood component being irradiated, with a minimum of 15 Gy at any part of the bag. 25 Of note, standards in the United Kingdom require a minimum dose of 25 Gy, with no more than 5 Gy delivered to any portion of the bag. 12 Special, radiation-sensitive labels are used to verify and permanently document that a blood product was irradiated. The expiration date of irradiated RBCs is shortened to 28 days from the date of irradiation, or the product s original expiration, whichever comes first. 25 In contrast, platelet component expiration is not affected by irradiation. Blood products that are inadvertently irradiated more than once, or at a dose not in accordance with standards, usually need to be discarded, unless the medical director of the facility determines otherwise. It must be noted that bone marrow, peripheral blood stem cells, or donor lymphocytes infused as part of a hematopoietic stem cell transplant program must never be irradiated. Most blood banks or blood centers use 137 Cs, 6 Co, or X-rays as a source of ionizing radiation to provide the required dose of radiation. 26 In order to remove sources of ionizing radiation from hospital blood banks or blood centers that could be used for domestic terrorism, the US government is reviewing the possibility of eliminating irradiators that use 137 Cs or 6 Co and replacing them with X-ray-based irradiators. In the future, γ irradiation may be one of several acceptable ways to prevent TA-GVHD. Pathogen inactivation systems using amotosalen 27,28 or riboflavin 29,3 and ultraviolet (UV) light have shown promise in inactivating lymphocytes and potentially preventing TA-GVHD. At present, however, pathogen inactivation systems are not available for use with RBCs, whole blood, or granulocytes and are not widely used in the United States for prevention of TA- GVHD in platelets. This is an area that may rapidly change in the future, given recent (214) regulatory action in the United States licensing amotosalen/uv-a light systems for pathogen reduction of fresh frozen plasma (FFP) and platelets. Special tags that are sensitive to UV light can be used to label usints of plasma or platelets that have been pathogen inactivated using amotosalen and UV light. Due to the rarity of cases of TA-GVHD, and the limited availability of irradiation in hospitals in some rural areas of the United States, there is not universal consensus on the specific medical conditions that require the use of irradiated cellular blood products. Some of the most common indications for irradiation are summarized in Table 6.3. In some areas of the world where cellular blood product irradiation is not universal, patients with TA-GVHD risk factors are occasionally transfused with nonirradiated blood. 31 Fortunately, the incidence of TA-GVHD is still very low among patients with risk factors who should have received irradiated blood. For example, in the United Kingdom between 26 and 21, there were 389 instances where patients inadvertently received nonirradiated cellular blood components (when irradiation was indicated). This cohort included 8 patients undergoing purine analog therapy, 68 patients with lymphoma (including Hodgkin s lymphoma), and 44 patients undergoing stem cell transplant. None of these patients developed TA-GVHD as a consequence of their transfusion, although the reason for this lack of negative outcomes is unclear. Possible explanations include lack of HLA similarity between donors and recipients, or decreased lymphocyte viability due to the storage time of the blood component before transfusion. Regardless, if a patient at risk for TA-GVHD is transfused with a nonirradiated cellular blood component, they should be monitored for signs of TA-GVHD for 3 days. Table 6.3 Stratification of risk for development of TA-GVHD based on medical condition, component infused, and medication exposures Highest Risk Association Lower-Risk Association No Known Risk Medical Conditions Medical Conditions Medical Conditions -Stem cell transplant -Acute leukemia -HIV/AIDS -Aplastic anemia -Neonatal status -Solid organ transplantation -Solid tumors -Congenital humoral immunodeficiencies -Intrauterine status -Non-Hodgkin s lymphoma -Hodgkin s lymphoma -Severe cellular immunodeficiency syndromes -T cell malignancies -Patients undergoing trauma resuscitations or cardiac surgery Blood Components Blood Components -Nonirradiated whole blood -Plasma -Nonirradiated RBCs -Clotting factor concentrates -Nonirradiated platelets -Cryoprecipitate -Nonirradiated granulocytes -Albumin -Nonirradiated cellular components used for intrauterine transfusions -Nonirradiated fresh (<72 hours from collection) cellular blood components -Intravenous immunoglobulin -Irradiated whole blood -Irradiated RBCs -Previously frozen, deglycerolized RBCs -Nonirradiated cellular components collected from first- or second- degree relatives, or in transfusion within population with limited HLA diversity (e.g., Japan) -Purine antagonists (e.g., clofarabine) -Alemtuzumab (anti-cd52) -Irradiated platelets -Irradiated granulocytes -Freeze-dried plasma Medications Medications Medications -Purine analogs (e.g., fludarabine, cladribine, and deoxycoformicin) Other cytotoxic or immunomodulatory agents (e.g., ATG or rituximab) Noncytotoxic, nonimmunomodulatory agents (e.g., antibiotics)

5 684 Section V: Part II: Other hazards Treatment of TA-GVHD There are only rare reports of patients surviving TA-GVHD. In one case, recovery was attributed to treatment with OKT3 and cyclosporin A. 32 Another case of atypical TA-GVHD resolved spontaneously, although the patient had a maculopapular rash, which is not classic for TA-GVHD. 33 However, overall, one of the distinguishing characteristics of TA-GVHD, compared to post bone marrow transplant GVHD, is that TA-GVHD does not usually respond to immunosuppressive therapy. 1 Unfortunately, treatment is supportive and the case fatality rate approaches 1%. Conclusion TA-GVHD is a rare but almost uniformly fatal consequence of transfusion with cellular blood components. Although the incidence of TA-GVHD in the United States, the United Kingdom, and Japan has become very low in the past 1 15 years, there are still sporadic case reports. Therefore, vigilance in terms of both avoidance of unnecessary transfusions and irradiation of blood components given to high-risk patients who are susceptible to TA-GVHD must continually be borne in mind. Key references A full reference list for this chapter is available at: transfusion 2 Uchida S, Tadokoro K, Takahashi M, Yahagi H, Satake M, Juji T. Analysis of 66 patients definitive with transfusion-associated graft-versus-host disease and the effect of universal irradiation of blood. Transfus Med 213 Dec;23(6): Ohto H, Yasuda H, Noguchi M, Abe R. Risk of transfusion-associated graft-versushost disease as a result of directed donations from relatives. Transfusion 1992 Sep;32(7): Treleaven J, Gennery A, Marsh J, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol 21 Jan;152(1): Australian and New Zealand Society of Blood Transfusion (ANZSBT). Guidelines for prevention of transfusion-associated graft-versus-host disease (TA-GVHD). Sydney, Australia: ANZSBT, Bolton-Maggs PHB (Ed.), Watt A, Thomas D, Cohen H; Serious Hazards of Transfusion (SHOT) Steering Group. The 212 annual SHOT report. Manchester, UK: SHOT, 213.

Blood Product Modifications: Leukofiltration, Irradiation and Washing

Blood Product Modifications: Leukofiltration, Irradiation and Washing 1. Leukocyte Reduction Definitions and Standards: o Process also known as leukoreduction, or leukofiltration o Applicable AABB Standards, 25th ed. Leukocyte-reduced RBCs At least 85% of original RBCs

More information

Guidelines for Gamma Irradiation of Blood Components

Guidelines for Gamma Irradiation of Blood Components AUSTRALIAN & NEW ZEALAND SOCIETY OF BLOOD TRANSFUSION INC. AUSTRALIAN RED CROSS BLOOD SERVICE NEW ZEALAND BLOOD SERVICE Guidelines for Gamma Irradiation of Blood Components Revised 2003 AN ZS B T Australian

More information

Specific Requirements

Specific Requirements Specific Requirements AIMS Specific requirements your patients have for transfusion and how this is managed Classify which patients require: Irradiated components CMV negative components Washed components

More information

GUIDELINES FOR IRRADIATED BLOOD COMPONENTS

GUIDELINES FOR IRRADIATED BLOOD COMPONENTS GUIDELINES FOR IRRADIATED BLOOD COMPONENTS 1. Policy Statement 2. Definitions 1.1 Blood transfusion services shall have a policy which indicates recipients who are to receive irradiated blood components.

More information

A Review of Guidelines and Evidence for the Use of Irradiated Blood Products in Solid Tumor, Chemotherapy Patients. Chris Kim 11/29/12

A Review of Guidelines and Evidence for the Use of Irradiated Blood Products in Solid Tumor, Chemotherapy Patients. Chris Kim 11/29/12 A Review of Guidelines and Evidence for the Use of Irradiated Blood Products in Solid Tumor, Chemotherapy Patients Chris Kim 11/29/12 Background Prevention of TAGVHD Irradiation: induces DNA crosslinks,

More information

RECOMMENDATIONS FOR USE OF IRRADIATED BLOOD COMPONENTS IN CANADA

RECOMMENDATIONS FOR USE OF IRRADIATED BLOOD COMPONENTS IN CANADA RECOMMENDATIONS FOR USE OF IRRADIATED BLOOD COMPONENTS IN CANADA 2016-09-26 Page 1 RECOMMENDATIONS FOR USE OF IRRADIATED BLOOD COMPONENTS IN CANADA BACKGROUND: The National Advisory Committee on Blood

More information

Transfusion-Associated Graft-versus-Host Disease TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE

Transfusion-Associated Graft-versus-Host Disease TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE D H Pamphilon for the NBS Transfusion Medicine Clinical Policies Group. Membership: M F Murphy (Chair), A Copplestone, M Gesinde, S MacLennan, C Morgan,

More information

Disclosures. Committee on Blood and Blood Products) Co-investigator CBS Small Project. in Solid Organ Transplant Recipients

Disclosures. Committee on Blood and Blood Products) Co-investigator CBS Small Project. in Solid Organ Transplant Recipients Neonatal Transfusion: Irradiation and CMV 6 th Annual Blood Matters Conference November 6 th, 2015 Disclosures Member of NAC (National Advisory Committee on Blood and Blood Products) Co-investigator CBS

More information

Blood Components & Indications for Transfusion. Neda Kalhor

Blood Components & Indications for Transfusion. Neda Kalhor Blood Components & Indications for Transfusion Neda Kalhor Blood products Cellular Components: Red blood cells - Leukocyte-reduced RBCs - Washed RBCs - Irradiated RBCs Platelets - Random-donor platelets

More information

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014 Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of

More information

An Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD

An Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD Harold Alvarez, MD Objectives Explain the etiology of platelet refractoriness Discuss the different types of platelet refractoriness Describe how platelet refractoriness is diagnosed Discuss different

More information

UKGS TRANSFUSION SERVICE PRODUCTS AND AVAILABILITY

UKGS TRANSFUSION SERVICE PRODUCTS AND AVAILABILITY Lexington, KY Page 1 of 13 Affected Sites: Enterprise Chandler X Good Samaritan I. PRINCIPLE: The UK Good Samaritan Hospital is dedicated to serve the patients with safe, high quality blood products and

More information

GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS

GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA Introduction: GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS These guidelines have been developed in conjunction with the hospital Transfusion Committee.

More information

The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.

The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness. The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness. Robert Liwski, MD, PhD, FRCPC Medical Director HLA Typing Laboratory Department of Pathology Dalhousie

More information

Stem Cell Transplantation for Severe Aplastic Anemia

Stem Cell Transplantation for Severe Aplastic Anemia Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center

More information

OneMatch Stem Cell and Marrow Network. Training Guide

OneMatch Stem Cell and Marrow Network. Training Guide OneMatch Stem Cell and Marrow Network Training Guide What is OneMatch all about? OneMatch is a Canadian Program that matches and coordinates the collection of stem cells from potential donors to help save

More information

Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT

Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT History Why is blood transfusion involved? What tests are performed in blood transfusion and why? What does a protocol look

More information

Overview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017

Overview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017 Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis

More information

All institutions that transfuse blood components and products should implement national and local policies and written procedures for:

All institutions that transfuse blood components and products should implement national and local policies and written procedures for: 5.0 GENERAL GUIDE TO GOOD TRANSFUSION PRACTICE Blood and the various components prepared or manufactured from it are biologic (in the case of blood cells, living human tissues) products intended for use

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia

More information

What s a Transplant? What s not?

What s a Transplant? What s not? What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence

More information

Transfusion support for the oncology patient

Transfusion support for the oncology patient PART III Oncology CHAPTER 50 Transfusion support for the oncology patient Wade L. Schulz & Edward L. Snyder Department of Laboratory Medicine, Yale School of Medicine, Yale University; and Blood Bank,

More information

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital

More information

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC

More information

Transplantation. Immunology Unit College of Medicine King Saud University

Transplantation. Immunology Unit College of Medicine King Saud University Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the

More information

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow 5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL

More information

An Overview of Blood and Marrow Transplantation

An Overview of Blood and Marrow Transplantation An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit

More information

Preventing CMV Transmission through Leukodepletion

Preventing CMV Transmission through Leukodepletion Preventing CMV Transmission through Leukodepletion Possibility & Facts Prof.S.B.Rajadhyaksha, MD,DTM,PGDMLS Head, Dept. of Transfusion Medicine Tata Memorial Hospital, Mumbai 1 Donor Leukocytes Linked

More information

Blood Transfusion Guidelines in Clinical Practice

Blood Transfusion Guidelines in Clinical Practice Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi

More information

Transplants. Mickey B. C. Koh

Transplants. Mickey B. C. Koh Transfusion in Stem Cell Transplants Mickey B. C. Koh Director: Stem Cell Transplant Programme Department of Haematology, St. George s Hospital and Medical School, London, UK Medical Director: Cell Therapy

More information

Policy for the use of Irradiated blood products

Policy for the use of Irradiated blood products Policy for the use of Irradiated blood products SharePoint Location General Policies and Guidelines SharePoint Index Directory Haematology and Blood Transfusion Sub Area - Key words (for search purposes)

More information

25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex

25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD

More information

Special Requirements Lab Matters. 18 th May Katy Cowan PBM Practitioner NHSBT

Special Requirements Lab Matters. 18 th May Katy Cowan PBM Practitioner NHSBT Special Requirements Lab Matters. 18 th May 2016 Katy Cowan PBM Practitioner NHSBT Special requirements Frozen components and platelets HEV negative Irradiated CMV negative Frozen components and platelets

More information

XIV. HLA AND TRANSPLANTATION MEDICINE

XIV. HLA AND TRANSPLANTATION MEDICINE XIV. HLA AND TRANSPLANTATION MEDICINE A. Introduction 1. The HLA system includes a complex array of genes and their molecular products that are involved in immune regulation and cellular differentiation.

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_ transplantation_for_primary_amyloidosis 2/2001 11/2018 11/2019 11/2018 Description

More information

Blood and Marrow Transplant (BMT) for Sickle Cell Disease

Blood and Marrow Transplant (BMT) for Sickle Cell Disease Blood and Marrow Transplant (BMT) for Sickle Cell Disease Rhiannon is now cured of sickle cell disease after BMT. Blood and marrow transplant (BMT) is a proven cure for sickle cell disease. This handbook

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001

More information

ADULT TRANSFUSION GUIDELINES ORDERED COMPONENT

ADULT TRANSFUSION GUIDELINES ORDERED COMPONENT ADULT TRANSFUSIN GUIDELINES RDERED Packed red cells (RBCs) RBCs, WBCs, platelets & plasma (minimal) Increase red cell mass and oxygen carrying capacity; generally indicated when Hgb is 7 gm or Hct 21 unless

More information

In The Name Of GOD ADVERSE REACTIONS OF TRANSFUSION

In The Name Of GOD ADVERSE REACTIONS OF TRANSFUSION In The Name Of GOD The 7 th international and 12 th national congress on quality improvement in clinical laboratories ADVERSE REACTIONS OF TRANSFUSION By Mehdi Allahbakhshian, PhD, Hematology and Blood

More information

Definitions of Current SHOT Categories & What to Report

Definitions of Current SHOT Categories & What to Report Definitions of Current SHOT Categories & What to Report Revised March 2011 1 ADVERSE EVENTS TERM DEFINITION WHAT TO REPORT IBCT - Wrong Blood Transfused (Incorrect Blood Component Transfused) Where a patient

More information

CTYOMEGALOVIRUS (CMV) - BACKGROUND

CTYOMEGALOVIRUS (CMV) - BACKGROUND CTYOMEGALOVIRUS (CMV) - BACKGROUND PURPOSE The flowing information provides guidance on the use of CMV negative blood components provided by the blood bank at the Royal Children s Hospital (RCH) including

More information

Aplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood

Aplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood What you need to know about Aplastic Anemia Stuart Goldberg MD Aplastic Anemia is a bone marrow failure disease The bone marrow is the factory that makes blood The 4 major components of blood Red Blood

More information

Another Lethal Complication of Neonatal Blood Transfusion: Clinical Diagnosis? Faculty of Medical Sciences, Lebanese University, Lebanon.

Another Lethal Complication of Neonatal Blood Transfusion: Clinical Diagnosis? Faculty of Medical Sciences, Lebanese University, Lebanon. JOURNAL OF CASE REPORTS 2015;5(1):8-12 Another Lethal Complication of Neonatal Blood Transfusion: Clinical Diagnosis? Hadi M. Fakih 1,2, Fawziah Chaaban 2 From The 1 Sheikh Ragheb Harb Hospital, Iranian

More information

Transplant Booklet D Page 1

Transplant Booklet D Page 1 Booklet D Pretest Correct Answers 4. (A) is correct. Technically, performing a hematopoietic stem cell transplant is one of the simplest transplantation procedures. The hematopoietic stem cells are infused

More information

Special Requirements Lab Matters. 21 st June Barrie Ferguson

Special Requirements Lab Matters. 21 st June Barrie Ferguson Special Requirements Lab Matters. 21 st June 2017 Barrie Ferguson Special requirements Patients requiring Methylene Blue or Solvent Detergent treated Fresh Frozen Plasma Patients requiring apheresis platelets

More information

An Introduction to Bone Marrow Transplant

An Introduction to Bone Marrow Transplant Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,

More information

DEPARTMENT OF CLINICAL HEMATOLOGY

DEPARTMENT OF CLINICAL HEMATOLOGY DEPARTMENT OF CLINICAL HEMATOLOGY What is blood? Blood is the vital fluid of the body, which performs diverse functions from delivering oxygen to each and every cell of the body to fighting against infections

More information

For more information about how to cite these materials visit

For more information about how to cite these materials visit Author(s): Robertson Davenport, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/

More information

All you wanted to know about transfusion support for transplants

All you wanted to know about transfusion support for transplants All you wanted to know about transfusion support for transplants Dr Dora Foukaneli NHSBT and Addenbrooke s Hospital Cambridge When / why / why not? What ABO group? Do other groups matter? Transplantation

More information

LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA Transfusion Criteria Version#2 POLICY NO.

LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA Transfusion Criteria Version#2 POLICY NO. LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA 1011.02 Transfusion Criteria Version#2 Department POLICY NO. PAGE NO. Blood Bank Quality Assurance Manual

More information

Rob Wynn RMCH & University of Manchester, UK. HCT in Children

Rob Wynn RMCH & University of Manchester, UK. HCT in Children Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action

More information

Blood Transfusion. What is blood transfusion? What are blood banks? When is a blood transfusion needed? Who can donate blood?

Blood Transfusion. What is blood transfusion? What are blood banks? When is a blood transfusion needed? Who can donate blood? What is blood transfusion? A blood transfusion is a safe, common procedure in which blood is given through an intravenous (IV) line in one of the blood vessels. A blood transfusion usually takes two to

More information

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,

More information

Apheresis: Transfusion Indications. Sasha Wilson: Transfusion Senior Nurse

Apheresis: Transfusion Indications. Sasha Wilson: Transfusion Senior Nurse Apheresis: Transfusion Indications Sasha Wilson: Transfusion Senior Nurse Apheresis: Transfusion Indications Focus of talk will be blood component transfusion in the context of apheresis procedures: Special

More information

Transfusion Therapy & Safety. Mary Grabowski, RN, BSN, BSIA Transfusion Safety Officer PSONEC Fundamentals September, 2015

Transfusion Therapy & Safety. Mary Grabowski, RN, BSN, BSIA Transfusion Safety Officer PSONEC Fundamentals September, 2015 Transfusion Therapy & Safety Mary Grabowski, RN, BSN, BSIA Transfusion Safety Officer PSONEC Fundamentals September, 2015 Topics Blood Components Special Processing/Attributes Irradiation Leukoreduction

More information

Clinical Relevance of the HLA System in Blood Transfusion. Dr Colin J Brown PhD FRCPath. October 2017

Clinical Relevance of the HLA System in Blood Transfusion. Dr Colin J Brown PhD FRCPath. October 2017 Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD

More information

Leukine. Leukine (sargramostim) Description

Leukine. Leukine (sargramostim) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)

More information

Understanding the role of ex vivo T cell depletion

Understanding the role of ex vivo T cell depletion Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This

More information

CHAPTER 10 BLOOD GROUPS: ABO AND Rh

CHAPTER 10 BLOOD GROUPS: ABO AND Rh CHAPTER 10 BLOOD GROUPS: ABO AND Rh The success of human blood transfusions requires compatibility for the two major blood group antigen systems, namely ABO and Rh. The ABO system is defined by two red

More information

The function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018

The function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018 The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry

More information

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell

More information

Acute Transfusion Reactions (Allergic, Hypotensive and Severe Febrile) (ATR) n=296 11

Acute Transfusion Reactions (Allergic, Hypotensive and Severe Febrile) (ATR) n=296 11 REACTIONS IN PATIENTS: Serious adverse reactions including EU definition ANNUAL SHOT REPORT 2015 Acute Transfusion Reactions (Allergic, Hypotensive and Severe Febrile) (ATR) n=296 11 Authors: Janet Birchall,

More information

EDUCATIONAL COMMENTARY TRANSFUSION-RELATED ACUTE LUNG INJURY

EDUCATIONAL COMMENTARY TRANSFUSION-RELATED ACUTE LUNG INJURY EDUCATIONAL COMMENTARY TRANSFUSION-RELATED ACUTE LUNG INJURY Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE

More information

New recommendations for immunocompromised patients

New recommendations for immunocompromised patients New recommendations for immunocompromised patients Hepatitis E Virus (HEV): Transmission, incidence and presentation Emerging evidence regarding HEV transmission from blood components and dietary consumption

More information

Transplantation Immunology Booklet C

Transplantation Immunology Booklet C Booklet C Pretest Correct Answers 3. (C) is correct. One of the major barriers to successful hematopoietic stem cell transplantation is the antigens coded for by the major histocompatibility gene complex.

More information

BMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016

BMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016 BMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016 David Rice, PhD, RN, NP Director, Professional Practice

More information

Haplo vs Cord vs URD Debate

Haplo vs Cord vs URD Debate 3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor

More information

Bone Marrow Transplantation and the Potential Role of Iomab-B

Bone Marrow Transplantation and the Potential Role of Iomab-B Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation

More information

Bone Marrow Transplantation

Bone Marrow Transplantation Bone Marrow Transplantation Introduction Bone marrow is the spongy tissue inside all of your bones, including your hip and thigh bones. The bone marrow is like a factory that makes different types of blood

More information

WISKOTT-ALDRICH SYNDROME. An X-linked Primary Immunodeficiency

WISKOTT-ALDRICH SYNDROME. An X-linked Primary Immunodeficiency WISKOTT-ALDRICH SYNDROME An X-linked Primary Immunodeficiency WHAT IS WISKOTT ALDRICH SYNDROME? Wiskott-Aldrich Syndrome (WAS) is a serious medical condition that causes problems both with the immune system

More information

Diagnosis of CMV infection UPDATE ECIL

Diagnosis of CMV infection UPDATE ECIL UPDATE ECIL-4 2011 Recommendations for CMV and HHV-6 management in patients with hematological diseases Per Ljungman, Rafael de la Camara, Hermann Einsele, Dan Engelhard, Pierre Reusser, Jan Styczynski,

More information

Aplastic Anemia: Current Thinking

Aplastic Anemia: Current Thinking Aplastic Anemia: Current Thinking ANDREW C. DIETZ, MD, MSCR PEDIATRIC BLOOD AND MARROW TRANSPLANTATION CHILDREN S HOSPITAL LOS ANGELES, UNIVERSITY OF SOUTHERN CALIFORNIA Outline Ø What is Aplastic Anemia?

More information

Objectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia

Objectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia SAA 101: An Introductory Course to Severe Aplastic Anemia David A. Margolis, MD Professor of Pediatrics/Medical College of Wisconsin Program Director/ Children s Hospital of Wisconsin BMT Program Objectives

More information

Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT

Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare

More information

Immunological transfusion reactions

Immunological transfusion reactions Immunological transfusion reactions Immunological transfusion reactions can be hemolytic or non-hemolytic in nature. Both types can be separated into acute (those occurring immediately after transfusion)

More information

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,

More information

with special requirements Contributes to: CQC Regulation 12 Consulted With Individual/Body Date Lead

with special requirements Contributes to: CQC Regulation 12 Consulted With Individual/Body Date Lead Special Requirements for Blood Transfusion Policy Register No: 16015 Status: Public Developed in response to: NHSBT & SaBTO guidance for patients with special requirements Contributes to: CQC Regulation

More information

Hematopoietic Stem Cell Therapy

Hematopoietic Stem Cell Therapy Hematopoietic Stem Cell Therapy Grace Totoe, MBChB, SBB CME August 2012 Accra-Ghana Hematopoietic Stem Cells Cells capable of self renewal and differentiation into all blood cell lineages Objectives Historical

More information

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant

More information

Transfusion reactions illustrated

Transfusion reactions illustrated Transfusion reactions illustrated Chapter 1 Transfusion practice 1 Procedure of transfusion practice In general, transfusion-associated incidents occur due to multiple errors, most of which occur in the

More information

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate

More information

Blood is serious business

Blood is serious business Transfusion at RCH BLOOD TRANSFUSION Anthea Greenway Dept of Clinical Haematology >10000 fresh blood products per year Supports craniofacial and cardiac surgery Support bone marrow, liver transplant and

More information

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus

More information

CELLULAR THERAPY QUIZ. Correct answers and rationale

CELLULAR THERAPY QUIZ. Correct answers and rationale CELLULAR THERAPY QUIZ Correct answers and rationale In January 2018, registered cellular therapy (CT) facilities were asked to participate in the quiz to determine the educational needs of the users regarding

More information

Clinical Policy: Donor Lymphocyte Infusion

Clinical Policy: Donor Lymphocyte Infusion Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte

More information

Consent Laboratory Transfuse RBC

Consent Laboratory  Transfuse RBC Peds Blood Product Infusion Order Set (386) [386] Blood product review will be performed unless exclusion criteria met. MD: Please note if transfusion giv en outside of parameter, please justify use in

More information

BMTCN Review Course Basic Concepts and Indications for Transplantation. David Rice, PhD, RN, NP

BMTCN Review Course Basic Concepts and Indications for Transplantation. David Rice, PhD, RN, NP BMTCN Review Course Basic Concepts and Indications for Transplantation March 16, 2017 David Rice, PhD, RN, NP Director, Professional Practice and Education No disclosures Objectives Describe basic concepts

More information

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility Bone Marrow Can Cure: Leukemia Lymphoma Multiple Myeloma Genetic iseases:

More information

ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015

ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM

More information

HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia

HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia BRIEF COMMUNICATION HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia Shang-Ju Wu, Ming Yao,* Jih-Luh Tang, Bo-Sheng Ko, Hwei-Fang

More information

PUO in the Immunocompromised Host: CMV and beyond

PUO in the Immunocompromised Host: CMV and beyond PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation

More information

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient 1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical

More information

New Advances in Transfusion EM I LY CO BERLY, M D

New Advances in Transfusion EM I LY CO BERLY, M D New Advances in Transfusion EM I LY CO BERLY, M D TRANSFUSI ON M EDI CI NE FELLO W VANDERBI LT UNI VERSITY Objectives To discuss the terminology, components, transfusion risks, and dosing guidelines for

More information

Riposta immune versus stato immune

Riposta immune versus stato immune Riposta immune versus stato immune Russell E. Lewis U.O. Malattie Infettive, Policlinico S. Orsola-Malpighi Dipartimento di Scienze Mediche e Chirurgiche Alma Mater Studiorum Università di Bologna Immunodeficiency

More information

Histocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director

Histocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director Histocompatibility Evaluations for HSCT at JHMI M. Sue Leffell, PhD Professor of Medicine Laboratory Director JHMI Patient Population Adults Peds NMDP data >20,000 HSCT JHMI HSCT Protocols Bone marrow

More information

HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People

HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People Histiocytosis UK Introduction Despite the misery it causes, Histiocytosis is too rare a disease to have generated substantial research in medical

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Autoimmune Diseases File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_autoimmune_diseases

More information

Transfusion-Related Acute Lung Injury (TRALI) and Strategies for Prevention. Khalid Abdulla Sharif, MD, MRCP (UK)*

Transfusion-Related Acute Lung Injury (TRALI) and Strategies for Prevention. Khalid Abdulla Sharif, MD, MRCP (UK)* Bahrain Medical Bulletin, Vol. 29, No.4, December 2007 Transfusion-Related Acute Lung Injury (TRALI) and Strategies for Prevention Khalid Abdulla Sharif, MD, MRCP (UK)* Background: Transfusion-Related

More information

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000

More information

Therapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.

Therapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD. Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific

More information